A phase II trial of vinorelbine plus gemcitabine in previously untreated inoperable (stage IIIb/IV) non-small-cell lung cancer patients aged 80 or older

Yuh Min Chen, Reury Perng Perng, Mei Chun Chen, Chun Ming Tsai, Jacqueline Ming-Liu, Jacqueline Whang-Peng

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Vinorelbine and gemcitabine are two active single agents with mild toxicity profiles that are used in the treatment of non-small-cell lung cancer (NSCLC). Whether or not very old NSCLC patients, such as those aged 80 years or older, should still be considered for chemotherapy is unknown, since their response to the treatment is also unknown. A phase II clinical trial was conducted to evaluate the efficacy and toxicity of vinorelbine plus gemcitabine in very old patients with inoperable (stage IIIb or IV) NSCLC. Vinorelbine 20 mg/m2 was given as a 10-min intravenous infusion, followed by a 30-min intravenous infusion of gemcitabine 800 mg/m2 on days 1, 8, and 15 of each 28-day cycle. From March 1998 to December 2001, 20 patients (16 males, four females) were enrolled in the study. The median age was 83 years, within the range 80-88 years. The median number of treatment cycles per patient was four. With the exception of one, all patients received at least two cycles of treatment. Thirteen patients achieved a partial response, with an overall response rate of 65% (95% confidence interval, 44.1-85.9%). Median survival was 10 months. The significant (WHO grade 3/4) toxicities were myelosuppression, including leukopenia in five (25%) patients, neutropenia in eight (40%), anaemia in six (30%), and thrombocytopenia in three (15%) patients. Febrile neutropenia occurred in two patients and accounted for one treatment-related death. Non-haematological toxicity was generally mild, except one patient who suffered from grade 3 interstitial pneumonitis. Another patient suffered from a cerebral infarction after three cycles of treatment. In conclusion, the combination of vinorelbine and gemcitabine in very old patients with advanced NSCLC is a highly active regimen with an acceptable toxicity profile.

Original languageEnglish
Pages (from-to)221-226
Number of pages6
JournalLung Cancer
Volume40
Issue number2
DOIs
Publication statusPublished - May 1 2003
Externally publishedYes

Fingerprint

gemcitabine
Non-Small Cell Lung Carcinoma
Intravenous Infusions
vinorelbine
Therapeutics
Febrile Neutropenia

Keywords

  • Gemcitabine
  • Non-small-cell lung cancer (NSCLC)
  • Vinorelbine

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

Cite this

A phase II trial of vinorelbine plus gemcitabine in previously untreated inoperable (stage IIIb/IV) non-small-cell lung cancer patients aged 80 or older. / Chen, Yuh Min; Perng, Reury Perng; Chen, Mei Chun; Tsai, Chun Ming; Ming-Liu, Jacqueline; Whang-Peng, Jacqueline.

In: Lung Cancer, Vol. 40, No. 2, 01.05.2003, p. 221-226.

Research output: Contribution to journalArticle

Chen, Yuh Min ; Perng, Reury Perng ; Chen, Mei Chun ; Tsai, Chun Ming ; Ming-Liu, Jacqueline ; Whang-Peng, Jacqueline. / A phase II trial of vinorelbine plus gemcitabine in previously untreated inoperable (stage IIIb/IV) non-small-cell lung cancer patients aged 80 or older. In: Lung Cancer. 2003 ; Vol. 40, No. 2. pp. 221-226.
@article{095c6322b2f0457bb4839ffe0a425432,
title = "A phase II trial of vinorelbine plus gemcitabine in previously untreated inoperable (stage IIIb/IV) non-small-cell lung cancer patients aged 80 or older",
abstract = "Vinorelbine and gemcitabine are two active single agents with mild toxicity profiles that are used in the treatment of non-small-cell lung cancer (NSCLC). Whether or not very old NSCLC patients, such as those aged 80 years or older, should still be considered for chemotherapy is unknown, since their response to the treatment is also unknown. A phase II clinical trial was conducted to evaluate the efficacy and toxicity of vinorelbine plus gemcitabine in very old patients with inoperable (stage IIIb or IV) NSCLC. Vinorelbine 20 mg/m2 was given as a 10-min intravenous infusion, followed by a 30-min intravenous infusion of gemcitabine 800 mg/m2 on days 1, 8, and 15 of each 28-day cycle. From March 1998 to December 2001, 20 patients (16 males, four females) were enrolled in the study. The median age was 83 years, within the range 80-88 years. The median number of treatment cycles per patient was four. With the exception of one, all patients received at least two cycles of treatment. Thirteen patients achieved a partial response, with an overall response rate of 65{\%} (95{\%} confidence interval, 44.1-85.9{\%}). Median survival was 10 months. The significant (WHO grade 3/4) toxicities were myelosuppression, including leukopenia in five (25{\%}) patients, neutropenia in eight (40{\%}), anaemia in six (30{\%}), and thrombocytopenia in three (15{\%}) patients. Febrile neutropenia occurred in two patients and accounted for one treatment-related death. Non-haematological toxicity was generally mild, except one patient who suffered from grade 3 interstitial pneumonitis. Another patient suffered from a cerebral infarction after three cycles of treatment. In conclusion, the combination of vinorelbine and gemcitabine in very old patients with advanced NSCLC is a highly active regimen with an acceptable toxicity profile.",
keywords = "Gemcitabine, Non-small-cell lung cancer (NSCLC), Vinorelbine",
author = "Chen, {Yuh Min} and Perng, {Reury Perng} and Chen, {Mei Chun} and Tsai, {Chun Ming} and Jacqueline Ming-Liu and Jacqueline Whang-Peng",
year = "2003",
month = "5",
day = "1",
doi = "10.1016/S0169-5002(03)00031-X",
language = "English",
volume = "40",
pages = "221--226",
journal = "Lung Cancer",
issn = "0169-5002",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

TY - JOUR

T1 - A phase II trial of vinorelbine plus gemcitabine in previously untreated inoperable (stage IIIb/IV) non-small-cell lung cancer patients aged 80 or older

AU - Chen, Yuh Min

AU - Perng, Reury Perng

AU - Chen, Mei Chun

AU - Tsai, Chun Ming

AU - Ming-Liu, Jacqueline

AU - Whang-Peng, Jacqueline

PY - 2003/5/1

Y1 - 2003/5/1

N2 - Vinorelbine and gemcitabine are two active single agents with mild toxicity profiles that are used in the treatment of non-small-cell lung cancer (NSCLC). Whether or not very old NSCLC patients, such as those aged 80 years or older, should still be considered for chemotherapy is unknown, since their response to the treatment is also unknown. A phase II clinical trial was conducted to evaluate the efficacy and toxicity of vinorelbine plus gemcitabine in very old patients with inoperable (stage IIIb or IV) NSCLC. Vinorelbine 20 mg/m2 was given as a 10-min intravenous infusion, followed by a 30-min intravenous infusion of gemcitabine 800 mg/m2 on days 1, 8, and 15 of each 28-day cycle. From March 1998 to December 2001, 20 patients (16 males, four females) were enrolled in the study. The median age was 83 years, within the range 80-88 years. The median number of treatment cycles per patient was four. With the exception of one, all patients received at least two cycles of treatment. Thirteen patients achieved a partial response, with an overall response rate of 65% (95% confidence interval, 44.1-85.9%). Median survival was 10 months. The significant (WHO grade 3/4) toxicities were myelosuppression, including leukopenia in five (25%) patients, neutropenia in eight (40%), anaemia in six (30%), and thrombocytopenia in three (15%) patients. Febrile neutropenia occurred in two patients and accounted for one treatment-related death. Non-haematological toxicity was generally mild, except one patient who suffered from grade 3 interstitial pneumonitis. Another patient suffered from a cerebral infarction after three cycles of treatment. In conclusion, the combination of vinorelbine and gemcitabine in very old patients with advanced NSCLC is a highly active regimen with an acceptable toxicity profile.

AB - Vinorelbine and gemcitabine are two active single agents with mild toxicity profiles that are used in the treatment of non-small-cell lung cancer (NSCLC). Whether or not very old NSCLC patients, such as those aged 80 years or older, should still be considered for chemotherapy is unknown, since their response to the treatment is also unknown. A phase II clinical trial was conducted to evaluate the efficacy and toxicity of vinorelbine plus gemcitabine in very old patients with inoperable (stage IIIb or IV) NSCLC. Vinorelbine 20 mg/m2 was given as a 10-min intravenous infusion, followed by a 30-min intravenous infusion of gemcitabine 800 mg/m2 on days 1, 8, and 15 of each 28-day cycle. From March 1998 to December 2001, 20 patients (16 males, four females) were enrolled in the study. The median age was 83 years, within the range 80-88 years. The median number of treatment cycles per patient was four. With the exception of one, all patients received at least two cycles of treatment. Thirteen patients achieved a partial response, with an overall response rate of 65% (95% confidence interval, 44.1-85.9%). Median survival was 10 months. The significant (WHO grade 3/4) toxicities were myelosuppression, including leukopenia in five (25%) patients, neutropenia in eight (40%), anaemia in six (30%), and thrombocytopenia in three (15%) patients. Febrile neutropenia occurred in two patients and accounted for one treatment-related death. Non-haematological toxicity was generally mild, except one patient who suffered from grade 3 interstitial pneumonitis. Another patient suffered from a cerebral infarction after three cycles of treatment. In conclusion, the combination of vinorelbine and gemcitabine in very old patients with advanced NSCLC is a highly active regimen with an acceptable toxicity profile.

KW - Gemcitabine

KW - Non-small-cell lung cancer (NSCLC)

KW - Vinorelbine

UR - http://www.scopus.com/inward/record.url?scp=0037404119&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037404119&partnerID=8YFLogxK

U2 - 10.1016/S0169-5002(03)00031-X

DO - 10.1016/S0169-5002(03)00031-X

M3 - Article

C2 - 12711125

AN - SCOPUS:0037404119

VL - 40

SP - 221

EP - 226

JO - Lung Cancer

JF - Lung Cancer

SN - 0169-5002

IS - 2

ER -